Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 5 mg - tablet, orally disintegrating - excipient ingredients: colloidal anhydrous silica; magnesium stearate; sucralose; mannitol; microcrystalline cellulose; carmellose calcium - - treatment of schizophrenia and related psychoses;. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder;. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: mannitol; sucralose; microcrystalline cellulose; colloidal anhydrous silica; carmellose calcium; magnesium stearate - - treatment of schizophrenia and related psychoses;. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder;. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 20 mg - tablet, orally disintegrating - excipient ingredients: sucralose; carmellose calcium; magnesium stearate; microcrystalline cellulose; mannitol; colloidal anhydrous silica - - treatment of schizophrenia and related psychoses;. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder;. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 10 mg - tablet, orally disintegrating - excipient ingredients: microcrystalline cellulose; carmellose calcium; sucralose; mannitol; magnesium stearate; colloidal anhydrous silica - - treatment of schizophrenia and related psychoses;. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder;. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 10 mg - tablet, orally disintegrating - excipient ingredients: colloidal anhydrous silica; sodium stearylfumarate; mannitol; aspartame; crospovidone; polacrilin potassium; microcrystalline cellulose; flavour - for the treatment of schizophrenia and related psychoses. alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: mannitol; sodium stearylfumarate; polacrilin potassium; colloidal anhydrous silica; aspartame; crospovidone; microcrystalline cellulose; flavour - for the treatment of schizophrenia and related psychoses. alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 5 mg - tablet, orally disintegrating - excipient ingredients: mannitol; aspartame; microcrystalline cellulose; crospovidone; sodium stearylfumarate; polacrilin potassium; colloidal anhydrous silica; flavour - for the treatment of schizophrenia and related psychoses. alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 20 mg - tablet, orally disintegrating - excipient ingredients: polacrilin potassium; colloidal anhydrous silica; mannitol; sodium stearylfumarate; crospovidone; aspartame; microcrystalline cellulose; flavour - for the treatment of schizophrenia and related psychoses. alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

avpak - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 5 mg -            oral olanzapine is indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see clinical studies (14.1)] .            when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5)] .             monotherapy — oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy w

Stati Uniti - Ingliż - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 5 mg - olanzapine orally disintegrating tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see clinical studies (14.1)]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5)]. monotherapy — olanzapine orally disintegrating tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clin